Viyash Scientific Q1 FY27 Results: Revenue ₹9,464 Crore, EBITDA ₹2,047 Crore
Viyash Scientific reported Q1 FY27 revenue of ₹9,464 crore and EBITDA of ₹2,047 crore, up 19.5% and 59.2% YoY, respectively. EBITDA margin improved to 21.6%. The company is acquiring Bio For Life in Italy, with closing expected in September 2026, to expand its companion animal segment.
The substantial year-on-year growth in key financial metrics (revenue and EBITDA) and the strategic acquisition in a new market are significant developments that will likely have a high impact on the company's performance and market position.
The company reported strong year-on-year growth in revenue and EBITDA, along with significant margin expansion. The strategic acquisition of Bio For Life also indicates positive future growth prospects.
Viyash Scientific Limited (formerly Sequent Scientific Limited) announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company reported revenues of ₹9,464 Million (₹946.4 crore) for Q1 FY27, marking a 19.5% year-on-year increase.
EBITDA for the quarter stood at ₹2,047 Million (₹204.7 crore), a significant 59.2% rise year-on-year, with the EBITDA margin improving by 530 basis points to 21.6%. The Net Debt to LTM EBITDA ratio decreased to 0.1x from 0.2x in Q4 FY26, with Net Debt at ₹861 Million (₹86.1 crore).
The company's acquisition of Bio For Life in Italy, with an execution date of July 21, 2026, and expected closing in September 2026, is a strategic step towards expanding its companion animal segment and accessing European markets. This acquisition is expected to provide market access and a platform for launching its product portfolio.
Key business segments showed strong performance, with Formulations revenue growing by 33% year-on-year to ₹5,547 Million (₹554.7 crore) and API revenue increasing by 4% to ₹3,833 Million (₹383.3 crore). The company also highlighted its R&D pipeline, manufacturing capabilities across 16 facilities globally, and a diversified product portfolio in human and animal health.
What to do with a filing like this
Viyash Scientific Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Viyash Scientific Limited. Read the original for the full detail.